{"id":"W2166262263","doi":"10.1016/s0140-6736(12)60868-x","title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","year":2012,"lang":"en","type":"article","venue":"The Lancet","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2960,"is_retracted":false,"has_abstract":false,"ca_institutions":"Jewish General Hospital","funders":"GlaxoSmithKline","keywords":"Dabrafenib; Dacarbazine; Medicine; Internal medicine; Melanoma; Hazard ratio; Clinical endpoint; Adverse effect; Oncology; Phases of clinical research; Progression-free survival; Clinical trial; Randomized controlled trial; Gastroenterology; Surgery; Metastatic melanoma; Chemotherapy; Cancer; Vemurafenib; Confidence interval; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}